TY - JOUR
T1 - Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma
AU - Mastrangelo, Stefano
AU - Rufini, Vittoria
AU - Tornesello, Assunta
AU - Riccardi, Riccardo
AU - Troncone, Luigi
AU - Pession, Andrea
PY - 1997
Y1 - 1997
N2 - Neuroblastoma (NB), a childhood radiosensitive tumor, is very aggressive
and malignant; in its disseminated form, despite very intensive
chemotherapy, prognosis continues to be dismal. Owing to its capacity to
concentrate in NE lesions, large doses of 131-I-MIBG, have given very
encouraging therapeutic results in patients resistant to conventional
therapy as well as at diagnosis.
We recently reported the first attempt in combination therapy (CO-TH)
using 131-I-MIBG and cisplatin. This new form of CO-TH appears very
effective in obtaining a rapid and excellent response in relapsed
patients.
In this report, we describe the results of further experience with CO-TH
in disseminated NE. We have attempted to verify to what extent
interaction between the effects of the two agents may produce
therapeutic benefit, and we have sought the optimization of CO-TH use.
Three stage IV NE patients were treated with CO-TH. The following
treatment schedule, was planned: day 1, cisplatin 50 mg/m(2) i.v. over 6
h; day 2, 131-I-MIBG 100-130 mCi at high specific activity (-1.1 Gbq/mg)
i.v. over 6 h followed, a week later, by the same treatment combination.
The therapeutic results were encouraging. However, hematological
toxicity continued to represent a major limiting factor. In view of the
overall effectiveness of CO-TH, at the price of lasting hematological
toxicity, it may be indicated as a consolidation regimen some time
before conditioning chemotherapy for autologous bone marrow
transplantation.
AB - Neuroblastoma (NB), a childhood radiosensitive tumor, is very aggressive
and malignant; in its disseminated form, despite very intensive
chemotherapy, prognosis continues to be dismal. Owing to its capacity to
concentrate in NE lesions, large doses of 131-I-MIBG, have given very
encouraging therapeutic results in patients resistant to conventional
therapy as well as at diagnosis.
We recently reported the first attempt in combination therapy (CO-TH)
using 131-I-MIBG and cisplatin. This new form of CO-TH appears very
effective in obtaining a rapid and excellent response in relapsed
patients.
In this report, we describe the results of further experience with CO-TH
in disseminated NE. We have attempted to verify to what extent
interaction between the effects of the two agents may produce
therapeutic benefit, and we have sought the optimization of CO-TH use.
Three stage IV NE patients were treated with CO-TH. The following
treatment schedule, was planned: day 1, cisplatin 50 mg/m(2) i.v. over 6
h; day 2, 131-I-MIBG 100-130 mCi at high specific activity (-1.1 Gbq/mg)
i.v. over 6 h followed, a week later, by the same treatment combination.
The therapeutic results were encouraging. However, hematological
toxicity continued to represent a major limiting factor. In view of the
overall effectiveness of CO-TH, at the price of lasting hematological
toxicity, it may be indicated as a consolidation regimen some time
before conditioning chemotherapy for autologous bone marrow
transplantation.
KW - 131-I-metaiodobenzylguanidine
KW - CISPLATIN
KW - NEUROBLASTOMA
KW - 131-I-metaiodobenzylguanidine
KW - CISPLATIN
KW - NEUROBLASTOMA
UR - http://hdl.handle.net/10807/16324
U2 - 10.1023/A:1005770405844
DO - 10.1023/A:1005770405844
M3 - Article
VL - 31
SP - 153
EP - 158
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
SN - 0167-594X
ER -